Member Info for flyingmachine

starressntoff, I have to agree, although no doubt Genedrive may have also taken the intervening time since then to apply any improvements to the Genedrive instrument as a result of feedback from the study. If there have been changes no doubt these will soon show up on the Genedrive website....

.....would be in the next few days, to align with European Human Genomics Conference which starts this Saturday August 28th. The session that presents the final report from the successful PALOH study conducted last year, using the Genedrive AIHL test, is on Tuesday 31st August (sesson C25).

It makes perfect sense to have the product launched to align with all the focus that's coming its way during the conference.

Get ready...

ST, this will also depend on the target depth for TAI-2. I asked a question in the 'Shallow Drill' thread to ask what people think that may be. I started by suggesting 300-400 meters on the basis that the 21st June RNS suggested the base of the Lake Bed formation was 400 meters (at the location where they are drilling), and my guesstimate that this formation is up to 100 meters thick.

Any other thoughts on target depth anyone? Other suggestions from other folk have been 150m (much too shallow I think) and 400-600m depth.

roleybirkin, do you mind if I ask where you worked that depth from please?

21st June RNS suggested base of Lake Bed is 400 meters depth, so my estimation is purely assuming the top of the Lake Bed is 300 meters, hence my 300-400 meters estimation.

Has anyone got a rough estimation of the target drill depth for TAI-2 drill. My own estimation suggests anywhere between 300-400 metres?

Suggins, this might help.....

https://www.trinitydelta.org/wp-content/uploads/2021/08/AVCT-Lighthouse-210811.pdf

Found this in the revised investment thesis for Avacta, published by Myles McNulty earlier today. Could be an interesting possibility....

I also found it interesting that Myles has mentioned in his revised thesis the possibility of a beneficial take-over of Abingdon Health. I don't think this has been considered before and I wonder if this possibility came into his head after the 'touch base' with Avacta last week?....

To establish – or acquire – proprietary manufacturing capacity for LFTs and other IVD products that Avacta plans to launch. With regards to the latter option, the obvious takeover candidate would be existing manufacturing partner, Abingdon Health. The business has a weakened balance sheet, having been messed around by the DHSC, which has seen its market capitalisation collapse from circa £100m, following its IPO last year, to a mere £25m. Not only would the acquisition of Abingdon result in an immediately increased manufacturing capacity for the AffiDX LFT, but it would be an extremely useful asset for Avacta in future product development (making it a much faster – and cheaper - process). Given the current valuations of both companies, an all-share offer would, in our view, be highly value accretive to both sets of shareholders.

I also found it interesting that Myles has mentioned in his revised thesis the possibility of a beneficial take-over of Abingdon Health. I don't think this has been considered before and I wonder if this possibility came into his head after the 'touch base' with Avacta last week?....

To establish – or acquire – proprietary manufacturing capacity for LFTs and other IVD products that Avacta plans to launch. With regards to the latter option, the obvious takeover candidate would be existing manufacturing partner, Abingdon Health. The business has a weakened balance sheet, having been messed around by the DHSC, which has seen its market capitalisation collapse from circa £100m, following its IPO last year, to a mere £25m. Not only would the acquisition of Abingdon result in an immediately increased manufacturing capacity for the AffiDX LFT, but it would be an extremely useful asset for Avacta in future product development (making it a much faster – and cheaper - process). Given the current valuations of both companies, an all-share offer would, in our view, be highly value accretive to both sets of shareholders.

LTH14, that is my view also, that AIHL test news will come first - I think that is most within Genedrive's immediate control. Other news landing will be a welcome surprise, though entirely possible that could happen.

Following the success of the PALOH study, using the Genedrive AIHL test, John McDermott has bagged a 3 year doctoral research scholarship from NIHR. From 1st October he will be building on his experience from the PALOH study by "exploring the pre-emptive pharmacogenetic testing and defining optimal models for implementation in the NHS".

This augers well for more POC genetic test assays to be developed by Genedrive in the future. No doubt John has a close working relationship with Genedrive, so I believe the successful AIHL test (MT-RNR1 ID) is just the first in this line of genetic testing possibilities.

What is pharmacogenetics? It is....

"Pharmacogenomics is the study of how genes affect a person's response to drugs. This relatively new field combines pharmacology (the science of drugs) and genomics (the study of genes and their functions) to develop effective, safe medications and doses that will be tailored to a person's genetic makeup."

Yes, absolutely G. Miele works for Genedrive.

Just going back to what I said in my first post...."I have expected that the completion and availability of this study report to be the trigger for commercialisation of the Genedrive AIHL test within the UK and EU."

I could be wrong about that expectation - it is just as likely that Genedrive are not waiting for the final publication of the report before launching the AIHL test, let's wait and see!

Considering this further, it is likely that Genedrive are contributors or co-authors of the final study report, so are very probably fully aware of its contents. It wouldn't surprise me that further improvements to the Genedrive AIHL test have been made because of the study outcomes......any changes/improvements are likely to show up on the Genedrive website, so keep an eye out.

Anyway, though quiet for a long period I think the AIHL test in particular will become very visible very soon.

I believe it is rated as an important study report at the Conference since John is being put forward as an 'Early Career Award' candidate.....

"Traditional genetic testing approaches have historically precluded the use of genomic data in the acute setting, due to the length of time testing can take. Here, we present results from the PALOH trial which demonstrate it is possible to genotype a variant of interest in approximately 25 minutes from a buccal swab. Approximately 1 in 500 individuals possess the m.1555A>G variant which, if exposed to aminoglycoside antibiotics, results in profound sensorineural deafness. This work demonstrates that rapid genotyping is possible and can be used in acute medical settings to improve patient outcomes, without disrupting normal practice. This work opens up opportunities for other initiatives which look to apply genomics in non-traditional healthcare settings.
John will speak about “Pharmacogenetics to Avoid Loss of Hearing (PALOH): A Prospective Observational Trial to Assess the Implementation of Rapid Genotyping to Avoid Aminoglycoside Induced Ototoxicity in” in the session C25 Using genomics to personalise medicine."

https://2021.eshg.org/programme/tuesday-august-31-virtual-conference/

I expect many LTH of Genedrive are already aware, but just in case.......John McDermott, whose team led the NIHR sponsored PALOH study last year, using the Genedrive AIHL test, is presenting the final results of that study at the European Human Genomics Conference on Tuesday 31st August (session C25).

This suggests to me that the final report will be complete before that date and I expect Genedrive will be made aware. I have expected that the completion and availability of this study report to be the trigger for commercialisation of the Genedrive AIHL test within the UK and EU.

Wiggly, this might help, it was posted yesterday....

https://www.trinitydelta.org/wp-content/uploads/2021/08/AVCT-Lighthouse-210811.pdf

Find the true story rather than the rumour.....

https://www.factcheck.org/2021/07/scicheck-viral-posts-misrepresent-cdc-announcement-on-covid-19-pcr-test/

The AIHL test is CE marked, so there are no restrictions on sale and distribution in Europe as soon as marketing commences following the formal publication of the report from the PALOH study which successfully completed at the start of this year. Without anything else, I expect the commercialisation of the AIHL test to firmly push the SP of GDR upwards from its current level.

Any positive news from WHO regarding the Genedrive SARS-COV-2 test should also lead to a higher SP, since this would support BC in their sales push of the test on the BIOTEK machines to the ROW. At the end of last year, when I analysed how long after 'request for further information' before accreditation was received from WHO, it was 3-4 weeks. It has been 3 weeks now since GDR responded to the new info request, so it could be within the next week or so when we get the final accreditation....that's my current expectation.

Tricky, positive results from the PALOH study are already well known, re: RNS on 03/12/2020 and 03/03/2021, so hopefully will see formal publication soon, before summer launch in UK.